Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer

Published:2023-10 Issue: Volume: Page:
ISSN:2949-7132
Container-title:Cancer Pathogenesis and Therapy
language:en
Short-container-title:Cancer Pathogenesis and Therapy

Author:

Shukla Siddhant,Patel Harsh^ORCID,Chen Shuzhen,Sun Rainie,Wei Liuya^ORCID,Chen Zhe-Sheng^ORCID

Publisher

Elsevier BV

Reference26 articles.

1. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial;Oaknin;JAMA Oncol,2020

2. Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study;Boll;Eur J Obstet Gynecol Reprod Biol,2013

3. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study;Muggia;J Clin Oncol,2002

4. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P;Dizon;J Clin Oncol,2009

5. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a gynecologic Oncology Group study;Fracasso;Gynecol Oncol,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3